We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Disease Causes Recurrent Respiratory Infections

By LabMedica International staff writers
Posted on 29 Oct 2013
A rare genetic disease has been discovered which predisposes patients to severe respiratory infections and lung damage.

The genetic mutation identified affects the immune system, and physicians are hopeful that new drugs that are currently undergoing clinical trials to treat leukemia may also be effective in helping individuals with this debilitating disease.

International collaborating scientists led by those at the University of Cambridge (Cambridge, UK) examined genetic information from individuals who suffer from immunodeficiency and are predisposed to infections. More...
From this group, they identified a unique genetic mutation in 17 patients that suffer from severe respiratory infections and rapidly develop lung damage.

DNA samples were isolated from blood or peripheral blood mononuclear cells (PBMCs). Exome target enrichment was carried out using either the SureSelect kit (Agilent; Santa Clara, CA, USA) or the Truseq kit (Illumina; San Diego, CA, USA). The lipid kinase activity was determined using a modified membrane capture assay and many other complementary assays were also performed.

The team found that the genetic mutation increases activity of an enzyme called Phosphoinositide 3-Kinase δ (PI3Kδ). The enzyme is present in immune cells and regulates their function. However, constantly activated PI3Kδ impairs work of these immune cells, preventing them from responding efficiently to infection and providing long-lasting protection. Consequently, patients with this mutation have severe and recurrent infections.

Sergey Nejentsev, MD, PhD, a Wellcome Trust Senior Research Fellow from the University of Cambridge who led the study said, “We called this newly identified disease Activated PI3K-δ Syndrome (APDS) after the enzyme in the immune system that is affected by the genetic mutation. It is very important that doctors consider a possibility of APDS in their patients. A simple genetic test can tell if the patient has the mutation or not. We believe that now many more APDS patients will be identified all over the world.” The study was published on October 17, 2013, in the journal Science Express.

Related Links:

University of Cambridge
Agilent  
Illumina 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.